Ivonescimab with chemotherapy before surgery for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called Ivonescimab (AK112) combined with two chemotherapy drugs (Abraxane and cisplatin) given before surgery for esophageal cancer. The goal is to see if this combination can shrink tumors and improve surgery outcomes for patients with locally advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a type of esophageal cancer called squamous cell carcinoma that is locally advanced but can be removed with surgery.
- You must have at least one tumor that can be measured on scans.
- You must be in good general health (ECOG score of 0 or 1) and have adequate organ function (like liver, kidney, and blood counts).
- You must not have received certain prior cancer treatments like immunotherapy or anti-angiogenic drugs.
- You must not have active autoimmune disease, serious heart problems, or other cancers in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a new immunotherapy drug (ivonescimab) along with standard chemotherapy before surgery can improve outcomes for people with resectable esophageal cancer. The goal is to shrink the tumor and increase the chance of successful surgery.
This trial combines a targeted immunotherapy drug (ivonescimab) with a short course of radiation to treat advanced esophageal cancer that has worsened after first treatment. It aims to see if this combination can help when standard options have stopped working.
This trial tests a combination of an immunotherapy drug (camrelizumab), chemotherapy, and another targeted drug (ivarmacitinib) before surgery for esophageal cancer. The goal is to see if this treatment can shrink the tumor before it is removed, potentially improving outcomes.
This trial tests combining a type of immunotherapy (adebrelimab) with chemotherapy before surgery, for esophageal cancer that can be removed. The goal is to see if this combo helps shrink the tumor and improve outcomes.
This study tests whether giving a combination of chemotherapy, radiation, and an immunotherapy drug (cadonilumab) before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a specific type of esophageal cancer that has not spread to other parts of the body.
This trial tests a new drug, ivonescimab, combined with chemotherapy for people with advanced mouth or throat cancer that can be removed with surgery. The goal is to see if the combination helps shrink tumors before surgery.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.